is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
SARS CoV-2 neutralizing antibodies (nAb) are specialized antibodies that block SARS CoV-2 from binding to our cells. SARS CoV-2 vaccines ultimately aim to incite growth of neutralizing antibodies to develop acquired immunity in patients.
Optical Q SARS CoV-2 nAb detection kit is a breakthrough fluorescence immunoassay (FIA) solution that can quantitatively measure neutralizing antibodies in blood samples within 15 minutes. This breakthrough test kit will allow for:
* Evaluating vaccine efficacy by detecting SARS-CoV-2 neutralizing antibodies in the serum/plasma from vaccinated patients;
* Monitoring immunization by mass detecting SARS-CoV-2 neutralizing antibodies in serum/plasma of recovering COVID-19 patients.